Key Highlights

  • The shares ended November 17, 2026 at a 156.36% advance following the Phase 3 REGAL study's primary endpoint win in acute myeloid leukemia.
  • Median overall survival hit 24.0 months for patients receiving the GPS vaccine, compared with 14.7 months for those on alternative therapies.
  • Early trade lifted the stock as much as 255.2%, and once the session ended the firm proposed a USD 150 million public offering.
  • In after-hours dealings the shares declined between 10.6% and 11.2% as dilution worries set in.

Survival Benefit Stands Out Where Options Are Scarce

REGAL is a Phase 3 examination of galinpepimut-S, known as GPS, among patients whose acute myeloid leukemia came back after achieving a second remission, a setting with few good choices. Investigators compared GPS with the best treatment physicians could select. Median survival stood at 24.0 months on GPS and 14.7 months in the comparator arm, a difference of over nine months. A hazard ratio of around 0.59 points to a sizeable drop in the chance of death. SELLAS Life Sciences (NASDAQ:SLS) reported that the study hit its primary endpoint, yet the outcome is not a regulatory approval and talks with the Food and Drug Administration about the data are planned. The regulator may not share the company's reading of the results. The disease carries a poor outlook, and few good options exist for patients after relapse.

Shares Spiked, Then Gave Ground on Dilution Concerns

The stock jumped 255.2% soon after the open, to near USD 26.53, before surrendering some of that gain. Later it stood roughly 149% above the prior close by mid-morning and roughly 167% above it in the early afternoon, finishing up 156.36%, the largest market move of the day. This came even though the S&P 500 sank to a five-month low and health care equities dropped 1.41%. Following the close, SELLAS Life Sciences (NASDAQ:SLS) announced a proposed underwritten sale of USD 150 million in common shares. Biotechs commonly raise Capital after encouraging data, when prices are high, to finance approval efforts and a launch. The sale dilutes current holders, and the shares dropped about 11% after hours, though they stayed far above their pre-study price. Trading Volume ran many times its normal level as retail and institutional buyers participated. The pricing of the offering will decide how much stock new investors receive.

Pricing, FDA Discussions and the Filing Schedule

Pricing is the first milestone, as the final price and size determine where new investors come in. Next are the FDA meeting and the complete trial results, which will likely be shown at a medical conference. Shareholders want information on side effects, results within important patient groups and how durable the survival advantage proves to be. A filing during the first half of 2027 would allow a possible approval decision in late 2027 or 2028, depending on the review schedule. SELLAS must keep enough cash to get there and to ready a commercial launch, which explains why the raise matters. Small biotech shares that surge on trial news often swing sharply in the following sessions as traders take profits. Investors also need to see whether the survival benefit holds up in full data, not just the topline result. The company's own timetable therefore carries real weight in how the stock trades next. Shareholders therefore face a tradeoff between near-term capital and ownership dilution.

Where Things Stand

SELLAS Life Sciences (NASDAQ:SLS) recorded a 156% gain on a Phase 3 survival result in acute myeloid leukemia, but it slipped after hours when a USD 150 million offering was announced. How that offering is priced, plus the FDA talks and the full data, will decide what comes next, and investors will weigh cash needs against dilution. Investors will also keep an eye on the filing timetable.